---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092712"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:43:33.194373+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis Q2 revenue $22.6M (+35% YoY); raises FY 2024 revenue guidance to $79-81M

## Summary
- Total revenue $22.6M, up 35% YoY; pharma testing $13.2M (+117% YoY).
- Net loss $12.8M, improved from $24.0M loss in Q2 2023; cash $87.0M.
- FY 2024 revenue guidance raised to $79-81M from $76-78M; non-GAAP net loss ~$75M.
- Cross-license agreement with Myriad Genetics; settled IP lawsuit with Foresight Diagnostics.
- Delivered 561 molecular tests in Q2, up 66% QoQ; launched NeXT Personal Dx with Tempus AI.

## SEC filing metadata
- accession: 0000950170-24-092712
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000095017024092712/0000950170-24-092712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000095017024092712/psnl-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092712
- JSON: https://secwatch.observer/filing/0000950170-24-092712.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092712.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.